Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
This study is testing two targeted cancer medicines together, called pirtobrutinib and venetoclax, to see if they can effectively control mantle cell lymphoma that has returned or stopped responding to past treatments. Mantle cell lymphoma is a type of blood cancer that affects the lymph nodes and the body's germ-fighting immune system.
You may be able to join if you are 18 or older, have a confirmed diagnosis of mantle cell lymphoma that has returned or did not respond to previous treatments, and can swallow pills by mouth. However, you cannot join if the cancer has spread to your brain or spinal cord, or if you have certain bleeding conditions or recent strokes.
Participants will take the study medications, which are targeted cancer medicines designed to block cancer cell growth and help cancer cells self-destruct. You will need to follow all study rules, take the pills as directed, and keep up with the scheduled visits.
The study is currently recruiting participants in Houston, Texas, United States.
- 1Tests a combination of two targeted medicines, pirtobrutinib and venetoclax.
- 2For adults with mantle cell lymphoma that has come back or not responded to prior treatments.
- 3Currently recruiting patients in Houston, Texas.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.